Cough - Pipeline Review, H2 2018

Cough - Pipeline Review, H2 2018


  • Products Id :- GMDHC10717IDB
  • |
  • Pages: 94
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Cough-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cough-Pipeline Review, H2 2018, provides an overview of the Cough (Respiratory) pipeline landscape.

Cough is a reflex action that clears the throat of mucus or foreign irritants. Signs and symptoms include stuffy nose, hoarseness, wheezing and shortness of breath and heartburn or a sour taste in mouth. Risk factors include laryngopharyngeal reflux, allergies, reduced hydration, smoking, asthma, chronic bronchitis, gastroesophageal reflux and chemical sensitivities. Treatment for cough includes antihistamines, decongestants, antibiotics and cough suppressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cough-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Cough (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cough (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cough and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Unknown stages are 2, 2, 12, 9 and 4 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Cough (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cough (Respiratory).

- The pipeline guide reviews pipeline therapeutics for Cough (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Cough (Respiratory) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Cough (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Cough (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Cough (Respiratory).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Cough (Respiratory) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cough-Overview

Cough-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cough-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cough-Companies Involved in Therapeutics Development

Alitair Pharmaceuticals Inc

Alveonix AG

AstraZeneca Plc

Bayer AG

Charleston Laboratories Inc

Conrig Pharma ApS

Develco Pharma Schweiz AG

Evotec AG

GlaxoSmithKline Plc

Grunenthal GmbH

Hyundai Pharmaceutical Co Ltd

Menlo Therapeutics Inc

Merck & Co Inc

Orbis Biosciences Inc

Patara Pharma Inc

PhytoHealth Corp

Shionogi & Co Ltd

SolAeroMed Inc

Tris Pharma Inc

Cough-Drug Profiles

(codeine + guaifenesin)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(guaifenesin + hydrocodone)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ax-8-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1817080-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1902607-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

benzonatate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bradanicline-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCP-05-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCP-06-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCP-07-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCP-08-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cromolyn sodium-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gefapixant-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2798745-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

guaifenesin ER-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydrocodone bitartrate + Undisclosed drug-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lesogaberan-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levodropropizine CR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-16523-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-5937-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORB-110-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

orvepitant-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pemirolast sodium-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PHCA-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-1226-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-600918-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

serlopitant-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Chronic Cough-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-015-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cough-Dormant Projects

Cough-Discontinued Products

Cough-Product Development Milestones

Featured News & Press Releases

Jul 19, 2018: BELLUS Health Announces Patent Protection Secured in All Major Pharmaceutical Markets for Lead Drug Candidate BLU-5937

Jul 19, 2018: Evotec Receives Milestone Payment For Start Of Phase II Trial In Its Multi-Target Alliance With Bayer

Jul 09, 2018: BELLUS Health Initiates Phase 1 Clinical Study for its Chronic Cough Drug Candidate, BLU-5937

Jun 27, 2018: BELLUS Health Presents BLU-5937 Preclinical Data and Updated Phase 1 Timeline at 2018 International Cough Symposium

Jun 20, 2018: BELLUS Health to Present at the 2018 International Cough Symposium

Feb 20, 2018: Menlo Therapeutics' Phase 2 Serlopitant Study for the Treatment of Chronic Pruritus Published in the Journal of the American Academy of Dermatology

Oct 26, 2017: Menlo Therapeutics Initiates Enrollment in Phase 2 Clinical Trial with Serlopitant for Refractory Chronic Cough

Oct 17, 2017: Menlo Therapeutics Expands its Management Team

Sep 21, 2017: Patara Pharmas Phase 2 Study Results for Treatment of Persistent Cough in IPF Patients Published in The Lancet Respiratory Mediciney Results for Treatment of Persistent Cough in IPF Patients Published in The Lancet Respiratory Medicine

Sep 18, 2017: BELLUS Health's BLU-5937 Significantly Reduces Cough Without Taste Disturbance in Two Preclinical Models

Sep 11, 2017: Attenua Announces Release of Data Demonstrating that ATA-101 is Antitussive in Guinea Pigs

May 22, 2017: Merck Announces Presentation of Phase 2 Results for MK-7264, an Investigational, P2X3 Receptor Antagonist, Being Evaluated for the Treatment of Chronic Cough

Apr 27, 2017: BELLUS Health to present at Bloom Burton & Co. Healthcare Investor Conference

Apr 24, 2017: BELLUS Health Announces Grant of New U.S. Patent Covering Lead Compound for Chronic Cough

Sep 07, 2016: Patara Pharma Announces Positive Phase 2 Results for the Treatment of Refractory Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Cough, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

List of Tables

Number of Products under Development for Cough, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Cough-Pipeline by Alitair Pharmaceuticals Inc, H2 2018

Cough-Pipeline by Alveonix AG, H2 2018

Cough-Pipeline by AstraZeneca Plc, H2 2018

Cough-Pipeline by Bayer AG, H2 2018

Cough-Pipeline by Charleston Laboratories Inc, H2 2018

Cough-Pipeline by Conrig Pharma ApS, H2 2018

Cough-Pipeline by Develco Pharma Schweiz AG, H2 2018

Cough-Pipeline by Evotec AG, H2 2018

Cough-Pipeline by GlaxoSmithKline Plc, H2 2018

Cough-Pipeline by Grunenthal GmbH, H2 2018

Cough-Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2018

Cough-Pipeline by Menlo Therapeutics Inc, H2 2018

Cough-Pipeline by Merck & Co Inc, H2 2018

Cough-Pipeline by Orbis Biosciences Inc, H2 2018

Cough-Pipeline by Patara Pharma Inc, H2 2018

Cough-Pipeline by PhytoHealth Corp, H2 2018

Cough-Pipeline by Shionogi & Co Ltd, H2 2018

Cough-Pipeline by SolAeroMed Inc, H2 2018

Cough-Pipeline by Tris Pharma Inc, H2 2018

Cough-Dormant Projects, H2 2018

Cough-Dormant Projects, H2 2018 (Contd..1), H2 2018

Cough-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Alitair Pharmaceuticals Inc

Alveonix AG

AstraZeneca Plc

Bayer AG

Charleston Laboratories Inc

Conrig Pharma ApS

Develco Pharma Schweiz AG

Evotec AG

GlaxoSmithKline Plc

Grunenthal GmbH

Hyundai Pharmaceutical Co Ltd

Menlo Therapeutics Inc

Merck & Co Inc

Orbis Biosciences Inc

Patara Pharma Inc

PhytoHealth Corp

Shionogi & Co Ltd

SolAeroMed Inc

Tris Pharma Inc

Cough Therapeutic Products under Development, Key Players in Cough Therapeutics, Cough Pipeline Overview, Cough Pipeline, Cough Pipeline Assessment

select a license
Single User License
USD 2000 INR 138420
Site License
USD 4000 INR 276840
Corporate User License
USD 6000 INR 415260

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com